Press release
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the GM2 Gangliosidosis Market Report:
• The GM2 Gangliosidosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• According to the analysis, approximately seventy cases of GM2 gangliosidosis were documented in the United Kingdom, with around forty individuals diagnosed with Tay-Sachs disease, thirty with Sandhoff disease, and two with GM2 activator protein deficiency.
• According to DelveInsight's analysis, in the United States, the incidence of TSD is approximately 1 in every 320,000 live births, while the carrier frequency is around 1 in 250 individuals.
• Approximately 30 patients were identified with mutations in the HEXA gene, while around fifteen patients exhibited defects in the HEXB gene. Among Tay-Sachs patients, about twenty individuals manifested the infantile form of the disease, with the age of diagnosis spanning from 7 months to 3 years.
• Key GM2 Gangliosidosis Companies: Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi, and others
• Key GM2 Gangliosidosis Therapies: AZ-3102 (nizubaglustat), IB1001, Zavesca (Miglustat), venglustat GZ402671, and others
• The GM2 Gangliosidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage GM2 Gangliosidosis pipeline products will significantly revolutionize the GM2 Gangliosidosis market dynamics.
GM2 Gangliosidosis Overview
GM2 gangliosidosis is a group of rare, inherited neurodegenerative disorders caused by the accumulation of GM2 ganglioside, a type of fatty substance, in the nerve cells of the brain and spinal cord. This accumulation results from a deficiency in specific enzymes needed to break down GM2 ganglioside. GM2 gangliosidosis is divided into two main types: Tay-Sachs disease and Sandhoff disease.
Get a Free sample for the GM2 Gangliosidosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
GM2 Gangliosidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
GM2 Gangliosidosis Epidemiology Segmentation:
The GM2 Gangliosidosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of GM2 Gangliosidosis
• Prevalent Cases of GM2 Gangliosidosis by severity
• Gender-specific Prevalence of GM2 Gangliosidosis
• Diagnosed Cases of Episodic and Chronic GM2 Gangliosidosis
Download the report to understand which factors are driving GM2 Gangliosidosis epidemiology trends @ GM2 Gangliosidosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
GM2 Gangliosidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the GM2 Gangliosidosis market or expected to get launched during the study period. The analysis covers GM2 Gangliosidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the GM2 Gangliosidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
GM2 Gangliosidosis Therapies and Key Companies
• AZ-3102 (nizubaglustat): Azafaros A.G.
• IB1001: IntraBio
• Zavesca (Miglustat): Children's National Research Institute
• venglustat GZ402671: Sanofi
Discover more about therapies set to grab major GM2 Gangliosidosis market share @ GM2 Gangliosidosis Treatment Landscape
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the GM2 Gangliosidosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key GM2 Gangliosidosis Companies: Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi, and others
• Key GM2 Gangliosidosis Therapies: AZ-3102 (nizubaglustat), IB1001, Zavesca (Miglustat), venglustat GZ402671, and others
• GM2 Gangliosidosis Therapeutic Assessment: GM2 Gangliosidosis current marketed and GM2 Gangliosidosis emerging therapies
• GM2 Gangliosidosis Market Dynamics: GM2 Gangliosidosis market drivers and GM2 Gangliosidosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• GM2 Gangliosidosis Unmet Needs, KOL's views, Analyst's views, GM2 Gangliosidosis Market Access and Reimbursement
To know more about GM2 Gangliosidosis companies working in the treatment market, visit @ GM2 Gangliosidosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. GM2 Gangliosidosis Market Report Introduction
2. Executive Summary for GM2 Gangliosidosis
3. SWOT analysis of GM2 Gangliosidosis
4. GM2 Gangliosidosis Patient Share (%) Overview at a Glance
5. GM2 Gangliosidosis Market Overview at a Glance
6. GM2 Gangliosidosis Disease Background and Overview
7. GM2 Gangliosidosis Epidemiology and Patient Population
8. Country-Specific Patient Population of GM2 Gangliosidosis
9. GM2 Gangliosidosis Current Treatment and Medical Practices
10. GM2 Gangliosidosis Unmet Needs
11. GM2 Gangliosidosis Emerging Therapies
12. GM2 Gangliosidosis Market Outlook
13. Country-Wise GM2 Gangliosidosis Market Analysis (2020-2034)
14. GM2 Gangliosidosis Market Access and Reimbursement of Therapies
15. GM2 Gangliosidosis Market Drivers
16. GM2 Gangliosidosis Market Barriers
17. GM2 Gangliosidosis Appendix
18. GM2 Gangliosidosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
GM2 Gangliosidosis Pipeline https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"GM2 Gangliosidosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the GM2 Gangliosidosis market. A detailed picture of the GM2 Gangliosidosis pipeline landscape is provided, which includes the disease overview and GM2 Gangliosidosis treatment guidelines.
Latest Reports by DelveInsight
Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.
Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi here
News-ID: 3516484 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region.
The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,…
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies
DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with…
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers.
The global…
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market.
The CD40 Pipeline report embraces in-depth commercial and…
More Releases for GM2
GM2 Gangliosidosis Market to Witness Promising Upswing by 2034, DelveInsight For …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
